Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 13, Issue 4, Pages 228-241Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2015.215
Keywords
-
Categories
Funding
- Cancer Council Victoria
- National Breast Cancer Foundation (NBCF) Australia
- Breast Cancer Research Foundation (BCRF), New York
- National Health and Medical Council of Australia (NHMRC)
- NHMRC
- German Cancer Consortium (DKTK)
- European Commission
- Susan Komen for the Cure Grant
Ask authors/readers for more resources
The clinical relevance of the host immune system in breast cancer has long been unexplored. Studies developed over the past decade have highlighted the biological heterogeneity of breast cancer, prompting researchers to investigate whether the role of the immune system in this malignancy is similar across different molecular subtypes of the disease. The presence of high levels of lymphocytic infiltration has been consistently associated with a more-favourable prognosis in patients with early stage triple-negative and HER2-positive breast cancer. These infiltrates seem to reflect favourable host antitumour immune responses, suggesting that immune activation is important for improving survival outcomes. In this Review, we discuss the composition of the immune infiltrates observed in breast cancers, as well as data supporting the clinical relevance of host antitumour immunity, as represented by lymphocytic infiltration, and how this biomarker could be used in the clinical setting. We also discuss the rationale for enhancing immunity in breast cancer, including early data on the efficacy of T-cell checkpoint inhibition in this setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available